<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The FAB group has recently published guidelines for distinguishing <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_338'>granulocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CGL</z:e>) from <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) and atypical <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (aCML) </plain></SENT>
<SENT sid="1" pm="."><plain>Whereas <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CGL</z:e> is generally recognized to be a distinct entity, there is debate as to whether <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> and aCML are separate disorders or part of a spectrum of <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> with dysplastic features </plain></SENT>
<SENT sid="2" pm="."><plain>Data are presented on 10 cases who developed features of a <z:mp ids='MP_0005481'>CML</z:mp> during the course of their disease but who presented with a <z:mpath ids='MPATH_458'>normal</z:mpath> or a low leucocyte count without a <z:mp ids='MP_0000220'>monocytosis</z:mp> and were diagnosed as refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>This suggests that, at least in some cases, aCML represents an unusual evolution of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and even though these patients have a uniformly poor prognosis it may be premature to regard aCML as a distinct clinical entity </plain></SENT>
</text></document>